India Q1 Results Preview: Exclusivity, Compliance Are Key Talking Points
First-quarter results of frontline Indian firms are expected to be a mixed bag as some are boosted by launches of products with marketing exclusivity in the US, while others are weighed down by increased competition and pricing erosion in the base business. Updates on compliance efforts at facilities and evolving regulations in India – the ban on certain fixed-dose combinations and controversial pricing orders – are other key issues to look out for.
You may also be interested in...
Cipla is implementing certain operational fixes and tweaks in its European and emerging markets businesses as it emerges from a weak fourth quarter that saw profits fall sharply, but limited visibility around the firm's Advair generic in certain key markets appeared to fluster some investors.
Lupin Ltd. has reported stellar numbers for the fourth quarter ended March 2016, buoyed by US sales of its generic version of Glumetza (metformin HCL extended-release tablets), the Valeant Pharmaceuticals International Inc. drug dumped earlier this year by pharmacy benefits manager, Express Scripts Holding Co.
Indian generic drug heavyweight Dr. Reddy’s quarterly net profit has tumbled nearly 90% on an exceptional charge involving a $65m write-down on receipts due from its Venezuelan subsidiary but improved financial performance indicators have cheered investors.